Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
TC BioPharm logo — Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP

TC BioPharm

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP

Founded 2014 United Kingdom United Kingdom 51 employees Post-IPO Equity Total: $46.61M Biotechnology, Health Care +1

General Information

Company Name TC BioPharm
Founded Year 2014
Location United Kingdom United Kingdom
Employees 51
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with TC BioPharm . To contact TC BioPharm , visit tcbiopharm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does TC BioPharm compare?

A PDF of TC BioPharm and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting TC BioPharm soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About TC BioPharm

TC BioPharm (Ticker: $TCBP) is a publicly traded, clinical-stage cell therapy company that was founded in 2013. The company is at the forefront of developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as pioneering gamma delta T cell therapies for the treatment of infectious diseases. With its headquarters in the United Kingdom, TC BioPharm has positioned itself as a prominent player in the biotechnology and health care industries. TC BioPharm's recent financing activity includes a £3.10M post-IPO equity investment on 06 May 2024. This signifies continued investor confidence in the company's innovative approach to combating cancer and infectious diseases. The company's growing team based in its Glasgow office, along with a diverse group of scientific advisors and partner organizations, underscores its commitment to advancing cutting-edge cell therapy solutions. Overall, TC BioPharm's focus on harnessing the potential of γδ T cells for treating cancer and infectious diseases positions it as a compelling player in the biotechnology and health care sectors, while its recent investment activity demonstrates ongoing investor interest in its advancements.

Business keywords: Cell Therapy, CAR-T Therapy, Cancer Treatment, Gamma Delta T Cells, Clinical-Stage, Allogeneic Therapy, Immunotherapy, Regenerative Medicine, Clinical Development, Solid Tumors, Infectious Disease, Biopharmaceuticals, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Melanoma

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity £3.10M -
06 May 2024
Post IPO Equity $1.26M -
18 Mar 2024
Post IPO Equity $3.50M -
19 Dec 2023
Post IPO Equity $5.00M -
28 Mar 2023
Post IPO Equity $7.50M -
30 Nov 2022
Venture Round Undisclosed 1
Renaissance Capital Partners
31 Oct 2019
Series B $16.00M 2
Renaissance Capital Partners, Bluebird Bio
07 Dec 2017
Grant €4.00M -
03 Aug 2017
Series A £6.25M 2
Nipro Corporation
Nipro Corporation, Scottish Investment Bank
31 Jan 2017

TC BioPharm Alternatives & Competitors

View All Alternatives
TC BioPharm vs
Kiromic Biopharma, Inc.
Kiromic Biopharma, Inc. United States

Cell therapy company with end-to-end bioinformatic, AI targeting, and manufacturing technologies to...

Post-IPO Equity
17 employees
Biopharma, Biotechnology
Compare TC BioPharm vs Kiromic Biopharma, Inc.
TC BioPharm vs
Adicet Bio, Inc
Adicet Bio, Inc United States

A biotechnology company discovering and developing first-in-class allogeneic gamma delta CAR t cell...

IPO
124 employees
Biopharma, Biotechnology
Compare TC BioPharm vs Adicet Bio, Inc
TC BioPharm vs
Acepodia
Acepodia United States

POWERFUL, ACCESSIBLE CELL THERAPIES FOR PATIENTS WITH CANCER

Series D
49 employees
Biotechnology, Health Care
Also compare with: TC BioPharm vs Wugen Wugen TC BioPharm vs Tessa Therapeutics Ltd Tessa Therapeutics Ltd TC BioPharm vs Turnstone Biologics Turnstone Biologics View all alternatives

FAQ About TC BioPharm

Treating cancer with γδ T cells | Nasdaq Ticker - $TCBP
TC BioPharm was founded in 2014.
TC BioPharm is headquartered in United Kingdom.
TC BioPharm operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Cell Therapy, CAR-T Therapy, Cancer Treatment and Gamma Delta T Cells.
TC BioPharm has approximately 51 employees.
TC BioPharm has completed 9 funding rounds, raising a total of $46.61M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to TC BioPharm include Kiromic Biopharma, Inc., Adicet Bio, Inc, Acepodia, Prescient Therapeutics, Wugen. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TC BioPharm and Kiromic Biopharma, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TC BioPharm , https://bouncewatch.com/company/tc-biopharm, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout